SCHEMBL544007

SCHEMBL544007

CN(C(=O)O)c1nc2ccc(O)cc2s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.69
HSD17B1 P14061 7/20 0.62
HSD17B2 P37059 6/20 0.62
DYRK1A Q13627 2/20 0.51
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
CASP3 P42574 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
APP P05067 2/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15280046 0.84 NPC1 (0.49) HTTHSD17B1HSD17B2NPC1LMNA
SCHEMBL2482877 0.82 HTT (0.61) HTTHSD17B1HSD17B2DYRK1AAPP
SCHEMBL5536580 0.82 HTT (1.00) HTTHSD17B1HSD17B2DYRK1ANPC1
SCHEMBL14509024 0.81 HTT (0.78) HTTHSD17B1HSD17B2DYRK1ATP53
SCHEMBL2939270 0.80 NPC1 (0.75) DYRK1ANPC1LMNATP53CASP3
SCHEMBL11732165 0.79 PPARA (0.57) HTTNPC1LMNATP53RAB9A
SCHEMBL8359106 0.78 HTT (0.68) HTTHSD17B1HSD17B2DYRK1ANPC1
SCHEMBL15280050 0.77 SMN1; SMN2 (0.43) HTTHSD17B1HSD17B2DYRK1ANPC1
SCHEMBL30192 0.77 HSD17B1 (1.00) HTTHSD17B1HSD17B2DYRK1ANPC1
SCHEMBL3357170 0.77 HSD17B1 (0.47) HTTHSD17B1HSD17B2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110571-B2 Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents AVENTIS PHARMA S.A. (FR) 2012-02-07 US disclosed